Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting real-world data to evaluate the safety and long-term effectiveness of catheter ablation using novel CARTO technologies for treating people with paroxysmal atrial fibrillation PAF, persistent atrial fibrillation PsAF, and ventricular arrhythmias VA. This observational registry gathers information from patients treated with commercially approved Biosense Webster, Inc. ablation catheters at various clinical centers. The goal is to understand clinical outcomes such as procedural efficiency, safety, and arrhythmia recurrence over time. Participants receive catheter ablation treatment following their healthcare providers standard care practices using CARTO systems like THERMOCOOL SMARTTOUCH SF, QDOT MICRO, and VARIPULSE. Future new technologies, including thermal or pulsed field ablation methods, may also be included as they become available. The registry has two groups one for subjects with symptomatic PAF or PsAF considered candidates for atrial fibrillation ablation, and another for subjects with documented ventricular arrhythmias suitable for ablation. During the study, researchers collect baseline and follow-up data based on routine clinical visits without additional procedures required by the registry. They track outcomes such as freedom from arrhythmia recurrence after a 90-day blanking period, serious complications within 7 to 30 days post-ablation, arrhythmia symptoms, medication use, and patient-reported quality of life measures. The total follow-up period extends up to at least 12 months to assess long-term safety and effectiveness of the catheter ablation procedures.